FMP

FMP

Enter

HJLI - enVVeno Medical Corp...

photo-url-https://images.financialmodelingprep.com/symbol/HJLI.png

enVVeno Medical Corporation

HJLI

NASDAQ

Inactive Equity

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 9 full-time employees. The firm is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The firm is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.

10.38 USD

-0.21000004 (-2.02%)

Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

-

-

-

-

-

-

-

-

-

-

Revenue %

-

-

-

-

-

-

-

-

-

Operating Cash Flow

-7.68M

-11.85M

-15.62M

-18.86M

-16.84M

-

-

-

-

-

Operating Cash Flow %

100

100

100

100

100

100

100

100

100

Cap Ex

-180.29k

-367.89k

-115k

-33k

-37k

-

-

-

-

-

Cap Ex %

100

100

100

100

100

-

-

-

-

Free Cash Flow

-7.86M

-12.21M

-15.73M

-18.89M

-16.88M

-

-

-

-

-

Weighted Average Cost Of Capital

Price

2.91

Beta

Diluted Shares Outstanding

17.14M

Costof Debt

4.09

Tax Rate

After Tax Cost Of Debt

4.09

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

1.06M

Total Equity

49.88M

Total Capital

50.95M

Debt Weighting

2.09

Equity Weighting

97.91

Wacc

10.49

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

-

-

-

-

-

-

-

-

-

-

Operating Cash Flow

-7.68M

-11.85M

-15.62M

-18.86M

-16.84M

-

-

-

-

-

Cap Ex

-180.29k

-367.89k

-115k

-33k

-37k

-

-

-

-

-

Free Cash Flow

-7.86M

-12.21M

-15.73M

-18.89M

-16.88M

-

-

-

-

-

Wacc

10.49

10.49

10.49

10.49

10.49

Pv Lfcf

-

-

-

-

-

Sum Pv Lfcf

-

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

10.49

Free Cash Flow T1

0

Terminal Value

0

Present Terminal Value

0

Intrinsic Value

Enterprise Value

0

Net Debt

-690k

Equity Value

690k

Diluted Shares Outstanding

17.14M

Equity Value Per Share

0.04

Projected DCF

0.04025201 -71.295%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep